Jefferies Maintains a 'Buy' on Celgene (CELG); Positive Feedback in Myeloma Survey

August 21, 2012 7:15 AM EDT
Get Alerts CELG Hot Sheet
Price: $111.84 -0.42%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 17 | New: 10
Trade CELG Now!
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Celgene (NASDAQ: CELG) price target of $81.00 (from $80.00).

Analyst, Thomas Wei, said, "We conducted a survey of 54 US multiple myeloma (MM) physicians. Feedback on Revlimid maintenance was incrementally positive for penetration and therapy duration, and we are raising our estimates and price target to $81 to account for longer duration of Revlimid therapy and higher pomalidomide penetration."

FY12 raised from $4.72 to $4.78 and FY13 from $4.73 to $4.79.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $70.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment